Michael Sundström

Michael Sundström

SGC Karolinska

Sundström

Michael Sundström

+46 70 65 44 662
SGC, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Tomtebodav. 23A, 171 65 Solna, Sweden

Affiliations

Biography

Michael Sundstrom received his PhD from Uppsala, followed by Postdoctoral studies at Karolinska Institute. From 1993-2000 he was at Pharmacia as Director for structure-based drug design and oncology R&D portfolio management. Between 2001 and 2003 he held senior positions at the Swedish Biotechs Actar and Biovitrum. In 2003 he joined the Structural Genomics Consortium (SGC) at the University of Oxford, as Chief Scientist. In 2007 he assumed the position as Managing Director for the Novo Nordisk Foundation Center for Protein Research (Copenhagen). In 2011, he was Vice President of Discovery Research at Karolinska Development. He then re-joined the SGC inmid-2014, as Scientific Director of European Initiatives at SGC.

Michael has three main responsibilities within the SGC; i) member of the global research leadership team coordinating projects and activities of common interest within the consortium; ii) site head for SGC Karolinska and iii) main scientific focus and responsibility for the SGC Tissue Platforms in Stockholm, Frankfurt, Toronto and Montreal; working to establish high quality cell-based assays using patient-derived cell systems in inflammation, oncology and neurodegenerative diseases.

Michael currently leads (ad interim) the efforts in the Tissue Assay platform at SGC Karolinska.
 

2025

Phenomics-based Discovery of Novel Orthosteric Choline Kinase Inhibitors.

Bauer LG, Ward JA, Díaz-Sáez L, Sundström Y, Tolvanen T, Barrera JCA, Kostidis S, Rogers CM, Panagakou I, Singh U, Rothweiler EM, Gonzalez Orta A, Kaniskan HÜ, Hu J, Jin J, Sievers S, Waldmann H, Giera M, Sundström M, Berg L, Huber K

Angew Chem Int Ed Engl. 2025-1-1 . e202420149 .doi: 10.1002/anie.202420149

PMID: 39740997

2022

Target 2035 - update on the quest for a probe for every protein.

Müller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell JB, Beck H, Beedie S, Betz UAK, Bezerra GA, Brennan PE, Brown D, Brown PJ, Bullock AN, Carter AJ, Chaikuad A, Chaineau M, Ciulli A, Collins I, Dreher J, Drewry D, Edfeldt K, Edwards AM, Egner U, Frye SV, Fuchs SM, Hall MD, Hartung IV, Hillisch A, Hitchcock SH, Homan E, Kannan N, Kiefer JR, Knapp S, Kostic M, Kubicek S, Leach AR, Lindemann S, Marsden BD, Matsui H, Meier JL, Merk D, Michel M, Morgan MR, Mueller-Fahrnow A, Owen DR, Perry BG, Rosenberg SH, Saikatendu KS, Schapira M, Scholten C, Sharma S, Simeonov A, Sundström M, Superti-Furga G, Todd MH, Tredup C, Vedadi M, von Delft F, Willson TM, Winter GE, Workman P, Arrowsmith CH

RSC Med Chem. 2022-1-27 . 13(1):13-21 .doi: 10.1039/d1md00228g

PMID: 35211674

2020

The RESOLUTE consortium: unlocking SLC transporters for drug discovery.

Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gürtl B, Klavins K, Klimek C, Lindinger S, Liñeiro-Retes E, Müller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, Hepworth D, Liu S, Noell S, Piotrowski M, Stanton R, Zhang H, Corallino S, Faedo A, Insidioso M, Maresca G, Redaelli L, Sassone F, Scarabottolo L, Stucchi M, Tarroni P, Tremolada S, Batoulis H, Becker A, Bender E, Chang YN, Ehrmann A, Müller-Fahrnow A, Pütter V, Zindel D, Hamilton B, Lenter M, Santacruz D, Viollet C, Whitehurst C, Johnsson K, Leippe P, Baumgarten B, Chang L, Ibig Y, Pfeifer M, Reinhardt J, Schönbett J, Selzer P, Seuwen K, Bettembourg C, Biton B, Czech J, de Foucauld H, Didier M, Licher T, Mikol V, Pommereau A, Puech F, Yaligara V, Edwards A, Bongers BJ, Heitman LH, IJzerman AP, Sijben HJ, van Westen GJP, Grixti J, Kell DB, Mughal F, Swainston N, Wright-Muelas M, Bohstedt T, Burgess-Brown N, Carpenter L, Dürr K, Hansen J, Scacioc A, Banci G, Colas C, Digles D, Ecker G, Füzi B, Gamsjäger V, Grandits M, Martini R, Troger F, Altermatt P, Doucerain C, Dürrenberger F, Manolova V, Steck AL, Sundström H, Wilhelm M, Steppan CM

Nat Rev Drug Discov. 2020-4-7 . .doi: 10.1038/d41573-020-00056-6

PMID: 32265506

2019

A genetics-led approach defines the drug target landscape of 30 immune-related traits.

Fang H, De Wolf H, Knezevic B, Burnham KL, Osgood J, Sanniti A, Lledó Lara A, Kasela S, De Cesco S, Wegner JK, Handunnetthi L, McCann FE, Chen L, Sekine T, Brennan PE, Marsden BD, Damerell D, O'Callaghan CA, Bountra C, Bowness P, Sundström Y, Milani L, Berg L, Göhlmann HW, Peeters PJ, Fairfax BP, Sundström M, Knight JC

Nat. Genet.. 2019-6-28 . .doi: 10.1038/s41588-019-0456-1

PMID: 31253980

2015

The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ

Nat. Chem. Biol.. 2015-7-21 . 11(8):536-41 .doi: 10.1038/nchembio.1867

PMID: 26196764

Preclinical target validation using patient-derived cells.

Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD, Sundström M, Barker P, Barsyte D, Bengtson MH, Bell C, Bowness P, Boycott KM, Buser-Doepner C, Carpenter CL, Carr AJ, Clark K, Das AM, Dhanak D, Dirks P, Ellis J, Fantin VR, Flores C, Fon EA, Frail DE, Gileadi O, O'Hagan RC, Howe T, Isaac JT, Jabado N, Jakobsson PJ, Klareskog L, Knapp S, Lee WH, Lima-Fernandes E, Lundberg IE, Marshall J, Massirer KB, MacKenzie AE, Maruyama T, Mueller-Fahrnow A, Muthuswamy S, Nanchahal J, O'Brien C, Oppermann U, Ostermann N, Petrecca K, Pollock BG, Poupon V, Prinjha RK, Rosenberg SH, Rouleau G, Skingle M, Slutsky AS, Smith GA, Verhelle D, Widmer H, Young LT

Nat Rev Drug Discov. 2015-2-20 . 14(3):149-50 .doi: 10.1038/nrd4565

PMID: 25722227

2014

Recently targeted kinases and their inhibitors-the path to clinical trials.

Knapp S, Sundström M

Curr Opin Pharmacol. 2014-8-8 . 17C:58-63 .doi: 10.1016/j.coph.2014.07.015

PMID: 25113945

2011

A secretory system for bacterial production of high-profile protein targets.

Kotzsch A, Vernet E, Hammarström M, Berthelsen J, Weigelt J, Gräslund S, Sundström M

Protein Sci.. 2011-2-11 . 20(3):597-609 .doi: 10.1002/pro.593

PMID: 21308845

2008

A pilot project to generate affinity reagents to human proteins.

Uhlen M, Gräslund S, Sundström M

Nat. Methods. 2008-10-1 . 5(10):854-5 .doi: 10.1038/nmeth1008-854

PMID: 18825127

2007

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S

Proc. Natl. Acad. Sci. U.S.A.. 2007-12-18 . 104(51):20523-8 .doi: 10.1073/pnas.0708800104

PMID: 18077363